Disclosure XL: Consulting/advisory role: Eli Lilly, EMD Serono, AstraZeneca, Spectrum Pharmaceutics, Novartis, Regeneron, Boehringer Ingelheim, Hengrui Therapeutics, Bayer, Teligene, Taiho, Daiichi Sankyo, Janssen, Blueprint Medicines, Sensei Biotherapeutics, SystImmune, ArriVent, Abion, and AbbVie. Research funding (Institution): Eli Lilly, EMD Serono, ArriVent, Dizal, Teligene, Regeneron, Janssen, ThermoFisher, Takeda, and Boehringer Ingelheim. Travel support: EMD Serono, Janssen, and Spectrum Pharmaceutics. Stock options: BlossomHill. AE: Advisory board honoraria and/or speaker fees: Amgen and the healthcare business of Merck KGaA, Darmstadt, Germany. AA: Honoraria: Merck & Co., Kenilworth, NJ, Novartis, Roche, Amgen, and Scigen. CDB: Advisory board: Amgen, AstraZeneca, Janssen, and Sanofi. Consultancy: the healthcare business of Merck KGaA, Darmstadt, Germany and Merck & Co., Kenilworth, NJ. Speaker fees: Janssen. PF: Consulting/advisory role: Roche, Takeda, Janssen, Pfizer, Novartis, Lilly, and Sanofi. MGC: Grants: Roche and AstraZeneca. Honoraria: Bristol Myers Squibb, Merck & Co., Kenilworth, NJ, Novartis, Pierre Fabre, Roche, and Sanofi. Support for meetings/travel: Merck & Co., Kenilworth, NJ, BMS, and Takeda. LH: Personal fees as an invited speaker/travel support: Benecke, Medtalks, and VJOncology. Fees paid to institution: Janssen, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Lilly, the healthcare business of Merck KGaA, Darmstadt, Germany, Merck & Co., Kenilworth, NJ, Novartis, Pfizer, Roche, Takeda, AstraZeneca, Bayer, and high5oncology. Institutional research grants: AstraZeneca, Boehringer Ingelheim, Roche, Takeda, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, and Pfizer. Institutional funding as a local PI: AbbVie, AstraZeneca, Blueprint Medicines, Gilead, GlaxoSmithKline, EMD Serono, Mirati, Merck & Co., Kenilworth, NJ, Novartis, Roche and Takeda. Nonremunerated roles as chair for metastatic NSCLC of the lung cancer group for EORTC and as the secretary of the studies foundation for NVALT. MJH: Personal fees and nonfinancial support: AstraZeneca, Boehringer Ingelheim, Takeda, and Roche. Personal fees: Merck & Co., Kenilworth, NJ. JM: Advisory boards: Roche, Bristol Myers Squibb, Merck & Co., Kenilworth, NJ, AstraZeneca, Pfizer, Novartis, the healthcare business of Merck KGaA, Darmstadt, Germany, Amgen, Takeda, and Daiichi Sankyo. Research funding (institution): Roche/Genentech, AstraZeneca, and Bristol Myers Squibb. HOS: Honoraria: Amgen, AstraZeneca. Expenses: Takeda. SP: Advisory role: Amgen, AstraZeneca, Bayer, BeiGene, Blueprint, BMS, Boehringer Ingelheim, Daiichi Sankyo, Guardant Health, Janssen, Lilly, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Roche, Takeda, and Merck & Co., Kenilworth, NJ. Coordinating PI: Ariad, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Takeda, and Turning Point Therapeutics. Local PI: AstraZeneca, GlaxoSmithKline, Roche and Trizel. Nonfinancial interests: acting in an advisory role with ALK Positive UK, Lung Cancer Europe, International Association for the Study of Lung Cancer and Ruth Strauss Foundation. Leadership role with British Thoracic Oncology Group and European Thoracic Oncology Platform. Officer with European Society of Medical Oncology. Member of board of directors with Mesothelioma Applied Research Foundation. JS: Advisory Boards: AstraZeneca, BeiGene, Bristol Myers Squibb, Eisai, Ipsen, Merck & Co., Kenilworth, NJ, Roche, and Taiho. AVDW: Consulting fees: AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Roche, Pfizer, Takeda. Invited speaker: Pfizer, AstraZeneca. Research grant: AstraZeneca, Boehringer Ingelheim, Roche, Pfizer, and Takeda. LMT: Advisory Board and Speaker honoraria: Pfizer, Roche, AstraZeneca, Boehringer Ingelheim, Novartis, and the healthcare business of Merck KGaA, Darmstadt, Germany. UH: Speaker fees: Merck & Co., Kenilworth, NJ, and BMS. WSL: Advisory Board: Amgen. Honoraria: BMS, Merck & Co., Kenilworth, NJ, Roche, Pfizer, Novartis, and AstraZeneca. KWCL: Advisory Board: AstraZeneca, Janssen, Merck & Co., Kenilworth, NJ, and Amgen. Honoraria for speaking engagements: AstraZeneca, Janssen, Takeda, Roche, and C-stone. Shareholder: Prenetics Ltd. KB, NK: Employees of the healthcare business of Merck KGaA, Darmstadt, Germany. KJ: Employee of ICON plc, contracted on behalf of the healthcare business of Merck KGaA, Darmstadt, Germany. SV: Was an employee of Merck N.V.-S.A., Overijse, Belgium, an affiliate of Merck KGaA, Darmstadt, Germany, at the time of study. TCH, NVR, TYY, UH: No conflicts of interest to disclose. GCC: Honoraria: F. Hoffmann-La Roche AG, Eli Lilly and Company Oncology, AstraZeneca, Novartis, Pfizer, Boehringer Ingelheim, Bristol Myers Squibb, and Merck & Co., Kenilworth, NJ.